Article info
PDFEditorial
Antibody–drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
- Correspondence to Dr Antonio Gonzalez-Martin, Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain; agonzalezma{at}unav.es
Citation
Antibody–drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
Publication history
- Received June 24, 2024
- Accepted June 24, 2024
- First published July 11, 2024.
Article Versions
- You are currently viewing a Previous version of this article (11 July 2024).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.